@re-joyce 14 July 2026

🧬 Chinese researchers have reported a promising breakthrough that could reshape the future of type 2 diabetes treatment. Doctors at Shanghai Changzheng Hospital treated a patient with an experimental stem cell-based therapy in July 2021. By growing insulin-producing cells from the patient’s own tissue and transplanting them back into the body, researchers were able to restore pancreatic islet function. Within 11 weeks, the patient no longer required insulin injections, and over the following year gradually stopped taking oral diabetes medications. More than 33 months later, the patient has remained free of insulin therapy. Scientists say the results represent a significant advance in regenerative medicine, though larger clinical trials are still needed to confirm whether the treatment is safe and effective for more people. The development is especially important given the global burden of diabetes. China alone has around 140 million people living with the condition, making it one of the countries most affected by the disease. The announcement has also renewed debate over insulin affordability, particularly in the United States, where insulin costs have been the focus of years of public criticism, lawsuits, and policy reforms. Although recent legislation and manufacturer price reductions have lowered costs for many patients, access and affordability remain ongoing concerns for millions. If future studies confirm that this type of cell therapy can be widely used, it could dramatically reduce the need for lifelong insulin treatment for some people with type 2 diabetes. However, experts caution that the therapy is still experimental and is not yet considered a widely available cure. 📚 Sources: Published clinical research, statements from the research team at Shanghai Changzheng Hospital, expert commentary from the University of British Columbia, and reporting by major international news outlets.